<DOC>
	<DOCNO>NCT02658175</DOCNO>
	<brief_summary>An Open-Label Study Volanesorsen ( IONIS 304801 ) Administered Subcutaneously Patients Familial Chylomicronemia Syndrome ( FCS )</brief_summary>
	<brief_title>The Approach Open Label Study : A Study Volanesorsen ( Formerly IONIS-APOCIIIRx ) Patients With Familial Chylomicronemia Syndrome</brief_title>
	<detailed_description>This multi-center , open-label study Group 1 : ISIS 304801-CS6 ( index study ) roll-over FCS patient , Group 2 : ISIS 304801-CS16 ( index study ) roll-over FCS patient , Group 3 : FCS patient participate ISIS 304801-CS6 ISIS 304801-CS16 index study . All patient receive volanesorsen 300 mg per week 52 week . Patients option continue dose additional 52 week expand access program approve available country .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type I</mesh_term>
	<criteria>Must give write informed consent participate study ( sign date ) authorization require law Able willing participate 65week study Group 1 2 : Satisfactory completion ISIS 304801CS6 ISIS 304801CS16 ( index study ) acceptable safety profile , per Sponsor Investigator judgment Group 3 : Patients participate CS6 CS16 index study meet additional inclusion criterion Familial Chylomicronemia Syndrome ( FCS ) may enroll study . History chylomicronemia A diagnosis Familial Chylomicronemia Syndrome ( Type 1 Hyperlipoproteinemia ) Fasting triglyceride ≥ 750 mg/dL ( 8.4mmol/L ) Screening Unwilling comply lifestyle requirement duration study Group 1 2 : Have new condition worsen exist condition opinion Investigator would make patient unsuitable enrollment , could interfere patient participate complete study . Group 3 : Diabetes mellitus newly diagnose HbA1c ≥ 9.0 % Active pancreatitis within 4 week screen Acute Coronary Syndrome within 6 month screen Major surgery within 3 month screen Treatment Glybera therapy within 2 year screen Have condition opinion investigator could interfere patient participate complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>